528 results about "Mouse Heart" patented technology

A mechanical circulatory support (MCS) system having an axial rotary blood pump with an impeller housing having a cylindrical pocket for receiving a magnet and closed by an end ring, requiring only a single circumferential weld and an axial weld. The impeller includes a shaft and one or more blades extending radially from the shaft. An inner and outer wall extend longitudinally from the shaft defining the pocket therebetween. A magnet array is positioned within the pocket and configured to be magnetically driven by an output shaft of a motor. The end ring is coupled to the end of the pocket opposite the shaft thereby encapsulating the magnet array within the pocket. Alignment holes may be provided within a floor of the pocket for orienting and balancing the impeller.

The invention discloses a construction method and application of a mouse model for specifically tracing heart valve cells, and belongs to the technical field of animal model construction. The model construction method comprises the following steps: (1) constructing a Wid1-Cre hybrid mouse before inserting a Cre recombinase coding gene into a termination codon of a mouse Wid1 gene; and (2) hybridizing the Wid1-Cre hybrid mouse with the Rosa26-tdTomato homozygous report mouse, so as to obtain the double transgenic mouse which simultaneously carries the Wid1-Cre gene and the Rosa26-tdTomato gene. According to the invention, on the basis of the expression characteristic that Wif1 is only limited to a valve area in the heart, Wif1-Cre is constructed; according to the Rosa26-tdTomato mouse model, specific tracing of heart valve cells is achieved, and an important experimental tool is provided for mechanism research of heart valve diseases and development of therapeutic drugs.

The application provides an application of a FAP-targeted CAR-T cell in preparation of a drug for treating cardiac fibrosis in a chronic phase of myocarditis. It is found in the application that FAP-specific CAR-T cells can effectively target cells expressing mouse FAP proteins, and the CAR-T cells can effectively eliminate cells expressing mouse FAP proteins after being activated, the chimeric antigen receptor T cells effectively reduce cardiac fibrosis in a chronic phase of myocarditis in mice, and restore the function after inflammatory injury. The application develops a CAR-T therapy for myocardial fibrosis caused by a chronic phase of myocarditis, and the chimeric antigen receptor T cells expressing a targeted fibroblast activation protein can recognize activated myocardial fibroblasts, and significantly reduce cardiac fibrosis after inflammatory injury and restore the function.

Provided is a method for screening myocardial therapeutic targets for ischemic heart failure by using single-cell sequencing, which method comprises the following steps: S1, sample preparation; S2, construction of a single-cell expression matrix; S3, cell quality control; S4, cell type annotation; S5, cell communication analysis; and S6, co-expression network analysis. The provided method for screening myocardial therapeutic targets for ischemic heart failure by using single-cell sequencing comprises performing single-cell sequencing on hearts of healthy mice and IHF mice, screening for cell types with significant differences in cardiac transcriptional profiles of the healthy mice and IHF mice, then exploring interaction characteristics of various types of cells in malignant fibrotic IHF hearts, revealing potential regulatory modules and pathways related to malignant myocardial fibrosis in single-cell expression data of IHF hearts, and performing screening to obtain Pdgfb and Tnfsf12 genes which can be used as therapeutic targets for treating myocardial fibrosis in ischemic heart failure.

The invention discloses an extraction method of safflower leaf exosome-like nano-vesicles and application of the safflower leaf exosome-like nano-vesicles in preparation of drugs for preventing and treating adriamycin-induced cardiotoxicity, fresh safflower leaves are taken and cleaned, a PBS solution is added for crushing and filtering, filtrate is collected and continuously centrifuged, supernate is taken and subjected to ultracentrifugation, precipitates are collected after centrifugation, and the safflower leaf exosome-like nano-vesicles are obtained; and filtering and sterilizing by using a filter membrane to obtain the safflower leaf exosome-like nano-vesicles. The carthamus tinctorius leaf exosome-like nano-vesicles can significantly improve the heart function of doxorubicin-induced cardiotoxic mice; myocardial injury induced by doxorubicin can be repaired, and myocardial fibrosis induced by doxorubicin can be inhibited; the content of a myocardial injury marker lactic dehydrogenase in body serum can be reduced, a new treatment strategy is provided for preventing and treating adriamycin-induced cardiotoxic diseases, and the application prospect is good.

Systems and methods for powering and controlling implantable heart pumps are provided. An example system may include an external controller housing for housing a processor programmable to control an implantable heart pump, a battery housing removably attachable to the external controller housing for housing battery cells to supply power to the implantable heart pump, a button connected to the battery housing, and a latch extending from the button to a latch protrusion. The button may be biased away from the battery housing in a locked position. In the locked position, the latch protrusion may engage with a latch receiver of the external controller housing to lock the external controller housing to the battery housing. The button may be depressed toward the battery housing to cause the latch protrusion to disengage from the latch receiver to permit the battery housing to be detached and removed from the external controller housing.

The invention belongs to the technical field of heart organ chips, and provides a heart organ chip optimization method based on mechanical matching, which is used for optimizing a double-layer substrate in a heart organ chip, a strain sensor and an electrophysiological electrode. A double-layer substrate in a heart organ chip, a strain sensor and an electrophysiological electrode are optimized, and the method comprises the steps that for the double-layer substrate simulating an extracellular matrix and an epicardium, the Young modulus is reduced by controlling phase change of tetradecane, introducing pores into polydimethylsiloxane and improving the cross-linking ratio of the polydimethylsiloxane; a strain sensor and an electrophysiological electrode based on carbon nanotube-polydimethylsiloxane are integrated into a double-layer substrate, and the Young modulus of the strain sensor and the Young modulus of the electrophysiological electrode are matched with the Young modulus of the double-layer substrate. The problem that the Young modulus of the substrate and the sensor material is too high is avoided, and mechanical matching among the soft myocardial tissue, the sensor and the substrate is achieved.

The present disclosure provides an interference mitigation cartridge for cardiac vibrational waves. The reduction box comprises an upper end face, side faces, a bottom face and a box body inner cavity defined by the upper end face, the side faces and the bottom face. The impedance wave-absorbing layer on the upper end surface comprises a carbon fiber epoxy layer, a silica gel carbon powder layer and a porous silicone rubber layer of which the impedance values are gradually reduced from large to small, and a through hole is formed in the center of the impedance wave-absorbing layer; the through hole penetrates through the upper lining layer to form an upper inner layer facing the inner cavity of the box body; the damping resonant cavity is formed after a gap between the lower surface of the porous silicon rubber layer and the upper surface of the upper lining layer is sealed at the side edge; the input vibration acquisition plate is embedded into a groove which is sunken downwards from the upper surface of the impedance wave-absorbing layer and is used for receiving and conducting input vibration containing heart vibration waves and environmental interference waves; and the vibration wave sensor is connected with the lower surface of the input vibration acquisition plate through a magnetic connecting piece, is arranged in the inner cavity of the box body and is used for receiving heart vibration waves.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention discloses a recombinant adeno-associated virus vector for targeted delivery of VEGF-C (vascular endothelial growth factor-C) and application of the recombinant adeno-associated virus vector in promoting endocardial differentiation to treat coronary heart disease. The rAAV vector comprises transgene for coding VEGF-C protein or VEGF-C protein functional variant and a tissue-specific promoter operably connected to the transgene, wherein the tissue specific promoter is capable of driving the transgene to be specifically expressed in the heart endothelial cells. According to the treatment method developed by the invention, specific expression of the Vegfc gene in the heart is driven by using an ICAM2 promoter with targeting to endothelial cells, and a remarkable curative effect is shown in a myocardial infarction model mouse. The therapeutic scheme provides a new effective strategy for intervention and treatment of myocardial infarction and chronic heart failure, and has the advantages of high safety, long gene expression duration, extremely low immune response to a host and the like.

The invention discloses application of 9 ''-salvianolic acid B monomethyl ester in preparation of a medicine for treating ischemic heart disease, and belongs to the technical field of biological medicine. The CAS number of the 9 ''-salvianolic acid B monomethyl ester is 1167424-31-8, the ischemic heart disease refers to myocardial injury induced by heart ischemia reperfusion, and the invention further provides a pharmaceutical composition or a small molecule injection preparation. Animal experiments show that 9 ''-salvianolic acid B monomethyl ester is exogenously injected to relieve myocardial injury of a mouse and improve the heart function of the mouse, and it is proved that the medicine containing 9''-salvianolic acid B monomethyl ester can improve the ischemic heart disease, especially myocardial injury caused by heart ischemia reperfusion, and has a good application prospect. The invention provides potential drug selection and research direction for preventing and treating ischemic heart disease, and has important clinical application value.

According to the multifunctional heart color ultrasound acoustic contrast examination device, the stirring mechanism is arranged in the cylinder, and the sealing mechanism and the mixing mechanism are integrated on the stirring mechanism, so that the efficiency and the sealing reliability in the contrast agent stirring process are remarkably improved. Wherein the mixing mechanism is fixedly connected to the outer wall of the stirring shaft and can drive the stirring plate to efficiently stir in multiple directions when the stirring shaft rotates, so that a contrast agent and gas can be fully mixed to generate mixed liquid with uniform and stable microbubbles, and the imaging quality and diagnosis accuracy of heart color ultrasound acoustic contrast examination are improved.

The present invention provides a method for providing information on an M-mode ultrasound image implemented by a processor and device using same, the method comprising the steps of: receiving an M-mode ultrasound image of a subject; segmenting a plurality of cardiac tomographic regions within the M-mode ultrasound image by using a segmentation model that is trained so as to segment the M-mode ultrasound image into a plurality of cardiac tomographic regions; and determining measurements for the plurality of segmented cardiac tomographic regions.

Systems and methods for delivering a docking device configured to receive a prosthetic valve are disclosed. A system can include a delivery catheter and a pusher device disposed in the delivery catheter and a docking device comprising a plurality of turns when in a coiled shape and having a proximal end portion and a distal end portion opposite the proximal end portion, where a retrieval line extends through a central lumen of the pusher device and is coupled to the proximal end portion of the docking device. The docking device is configured to move between a straightened shape when the docking device is arranged within the delivery catheter and the coiled shape after the docking device is pushed out of the docking device by the pusher device.

The invention provides an application of a CGRP inhibitor in preparation of a medicine for treating myocardial infarction or heart failure, relates to the technical field of biomedicine, and has the technical key points that the invention provides the CGRP inhibitor Rimegepant and provides an effect of the CGRP inhibitor Rimegepant in myocardial infarction and heart failure, and the CGRP inhibitor Rimegepant can be used for preparing a medicine for treating myocardial infarction or heart failure. The myocardial infarction and / or heart failure model is constructed through left anterior descending branch coronary artery ligation. In-vitro experiments verify that the expression of the CGRP receptor protein in the heart of a mouse after heart failure is increased, and prove that the CGRP inhibitor Rimegeant can effectively inhibit the expression of the CGRP receptor protein, and further research is carried out, so that a potential treatment strategy is provided for drug research and development. The in-heart CGRP receptor inhibitor can obviously relieve the myocardial infarction and / or heart failure course of mice, and down-regulate the protein expression of the CGRP receptor at the same time.

Embodiments of the present disclosure provide a mobile electrocardiogram (ECG) sensor comprising an electrode assembly comprising electrodes, wherein the electrode assembly senses heart-related signals when in contact with a body of a user, and produces electrical signals representing the sensed heart-related signals. The ECG sensor further comprises a processing device, operatively coupled to the electrode assembly, the processing device to provide the sensed heart-related signals to a machine learning module trained to predict a twelve-lead QT interval (QTc) value from the mobile ECG sensor comprising less than twelve leads. The ECG sensor also comprises a housing containing the electrode assembly and the processing device.

The invention discloses a construction method and application of an animal model for evaluating cardiotoxicity of antitumor drugs, sodium carboxymethyl cellulose (CMC-Na) with extremely low cost is adopted to replace matrigel, a tumor-bearing mouse model with high stability can be constructed at low cost, and experimental verification shows that 4T1 cells are resuspended by using a 0.7% CMC-Na solution, and the tumor formation rate of subcutaneous inoculation reaches gt; 95%. The tumor microenvironment-mediated cardiac injury critical period is accurately captured, and the constructed tumor-bearing mouse model is the optimal tumor-bearing mouse model for evaluating the cardiotoxicity of an antitumor drug (adriamycin) in the tumor microenvironment in the third week after the mouse has a 50mm < 3 > tumor.

Example cardiac pump systems are disclosed. An example cardiac pump system includes a cardiac pump coupled to a console. Further, the console includes a first display including a first visual representation of a first parameter of the cardiac pump system. Further, the first display includes a first status indicator and a second status indicator corresponding to the first parameter. Further, the first display is configured to display the first status indicator when the first parameter satisfies a first condition, and wherein the first display is configured to display the second status indicator when the first parameter satisfies a second condition.

The present invention discloses a heart valve molding component, which includes: a main base, three leaflet forming areas, and three leaflet partitions. The main base has a leaflet end for forming the leaflets, and the three leaflet forming areas are circumferentially spaced at the leaflet end of the main base. Each leaflet partition is formed between two adjacent leaflet forming areas. The leaflet partition has a central side close to the central axis of the main base and a peripheral side close to the peripheral wall of the main base. The width of the central side of the leaflet partition is not less than the width of the peripheral side of the leaflet partition. This increases the distance between the middle parts of the two adjacent leaflets, prevents the middle parts of the two adjacent leaflets from prematurely combining and supporting each other, and allows for better closure between the two adjacent leaflets, reducing leaflet regurgitation.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

The invention relates to the technical field of mode recognition, in particular to a cardiac image data processing system based on deep learning, which comprises an initial map construction module, an artifact branch pruning module, a fracture path repairing module and a topological smooth output module. According to the method, initial topology containing node coordinates is constructed, the maximum inscribed circle area is calculated to generate circulation attributes, virtual blood flow injection simulation and flow resistance calculation are utilized to accurately quantify branch traffic capacity, artifact interference is eliminated according to the matching relation between the blood flow proportion and the flow resistance, and suspended node geometric features and a path texture sequence are combined, so that the branch traffic capacity is accurately quantified. A graph neural network is utilized to predict a connection probability to repair a fracture path, a node coordinate weighted updating mechanism is matched to guarantee smoothness and continuity of a topological structure, the problems of artifact confusion and path fracture in a traditional method are effectively solved, and the construction accuracy and automation level of a heart structure model are remarkably improved.

The application provides a kind of replacement valve device and its support by catheterization, it is related to heart valve technical field.The replacement valve support by catheterization includes support main body, anchoring structure, skirt support structure and sealing membrane.The sealing membrane is circumferentially closed cylindrical structure, sealing membrane includes the first sealing section and the second sealing section being arranged along the axial direction and being connected with each other, the first sealing section is tightly arranged on part or all of skirt support structure, the second sealing section is tightly arranged on part or all of support main body;Sealing membrane is arranged on the inner side and / or outer side of skirt support structure and support main body.The application can solve the problem that sealing membrane and valve support do not fit in the prior art, poor sealing, leading to sealing membrane in blood, leading to paravalvular leakage or causing other complications, with high degree of fit, good sealing, can avoid sealing membrane in blood, effectively avoid paravalvular leakage or cause other complications.

The present invention provides novel RNA base editing compositions, systems, methods and uses. Guide RNAs for site-specific RNA editing of RNA encoding transcriptional coactivators YAP1 or TAZ are provided, and compositions and systems comprising the same with a programmable RNA binding protein (e.g. a Cas protein) and / or a base editor. Methods for RNA editing of YAP1 or TAZ are also provided. RNA editing of YAP1 or TAZ is used for targeting phosphorylation sites, and activating transcription of proteins in regenerative therapy for treating cardiac disease.

The present application provides a method for improving the yield and purity of cardiomyocytes derived from pluripotent stem cells, which comprises one or more of the following steps: EB formation culture; cardiac progenitor cell induction and differentiation culture; cardiomyocyte induction and differentiation culture; cardiomyocyte maturation culture; and cardiomyocyte purification culture. In another aspect, the present application also provides a culture medium, a medium combination, a cell culture system, and a kit for improving the yield and purity of cardiomyocytes derived from pluripotent stem cells.

Disclosed is a system for monitoring a heart condition in a companion animal. The system can collect electrocardiogram data of a companion animal through a capacitive electrocardiogram sensor without prior preparation such as hair removal, collect phonocardiogram data and ballistocardiogram data through a phonocardiogram sensor and a ballistocardiogram sensor, and generate cardiogram-integrated data available for diagnosing a heart condition in the companion animal by merging the electrocardiogram data, the phonocardiogram data, and the ballistocardiogram data.

A heart pump assembly includes an elongate catheter with a proximal portion and a distal portion, a rotor at the distal portion of the elongate catheter, a driveshaft, and a bearing. The rotor can include an impeller blade shaped to induce fluid flow in a first axial direction. The drive shaft may be coupled to or integrally formed with a proximal end of the rotor and can include a pump element formed in a surface of the drive shaft. The bearing can include a bore into which the drive shaft extends. The pump element is shaped so as to induce fluid flow through the bore in a second axial direction which can be the same or opposite to the first axial direction.

To provide an ultrasonic inspection device capable of easily obtaining an image of a heart larger than a general size.SOLUTION: An ultrasonic inspection device 1 includes: a support member 13 having a first support surface 21b facing upward and having an opening 13a vertically penetrating the support member 13 formed therein; a wave projection part 27a arranged below the first support surface 21b and emitting an ultrasonic wave upward through the opening 13a; and a detection part 27b arranged below the first support surface 21b and detecting the ultrasonic wave.SELECTED DRAWING: Figure 2

The application belongs to the technical field of biological medicine, and discloses application of targeted inhibition of TRIM47 in preparation of a drug for preventing or treating myocardial ischemia-reperfusion injury. By establishing a mouse myocardial ischemia-reperfusion injury model, it is found that, compared with a model group, specific knockout of the TRIM47 gene in the heart can significantly improve the heart function of a myocardial ischemia-reperfusion injury mouse, reduce the infarct area after myocardial reperfusion, and also reduce the hypertrophy of myocardial cells and matrix deposition of the mouse, and improve myocardial remodeling. Based on the above findings, TRIM47 can be used as an action target of a myocardial ischemia-reperfusion injury treatment drug, and an inhibitor thereof can be used for preparing a drug for preventing or treating myocardial ischemia-reperfusion injury.

The invention discloses a valve preparation method. The method comprises the following steps: performing decellularization treatment on a bovine pericardium material to be treated; enhancing the porosity of the decellularized bovine pericardium material through a physical and / or chemical method so as to promote the regeneration of native valve leaflet cells and tissues, and obtaining a composite material; and cutting the leaflet of the composite material to obtain the valve. The bovine pericardial valve which is high in durability, free of anticoagulation, excellent in biocompatibility, excellent in calcification resistance and low in immunogenicity can be prepared, and therefore the purpose of treating heart valve diseases is achieved.

The invention belongs to the technical field of electrochemical monitoring, and particularly relates to a physiological and biochemical diagnosis and treatment integrated implantable heart flexible sensor which comprises an insulating substrate, a counter electrode, a working electrode, a reference electrode and two electrocardiogram electrodes, graphene aerogel loaded with a monitoring substance is adhered to the working end of the working electrode, and the monitoring substance is a substance for monitoring biochemical signals. The implantable heart flexible sensor provided by the invention can realize trinity collaborative operation of physiological signal monitoring, biochemical signal monitoring and treatment functions. In the aspect of monitoring physiological signals, the system has the advantages of high signal-to-noise ratio, dynamic adaptability, long-term stability and the like; in the aspect of monitoring biochemical signals, the sensor has the advantages of high sensitivity and high stability; in the aspect of treatment, the device has the characteristics of promoting electrical signal conduction, being flexibly attached to the heart, providing three-dimensional structure support regeneration and being stable for a long time.